A registry set up in 2009 to help research sponsors and sites prevent healthy volunteers in North America from enrolling in concurrent or overlapping clinical trials has received a vote of confidence from the seven study sites that made up the original clinicalRSVP.com user network.
The Fort Lauderdale, US-based business, which aims to provide a single North American registry where investigators can confidentially and securely check subject eligibility requirements prior to enrolling volunteers, said the seven original sites had all agreed to extend their commitment to the clinicalRSVP network “through 2012 and beyond”.
This group of sites was the first in North America to adopt a subject registry for the purpose of preventing dual enrolment, noted clinicalRSVP.com. Three of the sites belong to Comprehensive Clinical Development, two to Seaview Research and one apiece to Clinical Pharmacology of Miami and Elite Research Institute.
The clinicalRSVP network has since grown to encompass 18 Phase I Units in total across the United States and Canada, representing more than 20% of Phase I beds in North America, the registry added.
The rationale is to enhance both data integrity and participant safety for clients. “Ensuring our participants’ safety and facilitating rapid study start-up are the primary focuses for us at Comprehensive Clinical Development,” commented Dr. Rae DelVecchio, that company’s senior vice president, Early Phase Operations.
“We want our sponsors and participants to have total confidence in every aspect of our business and clinicalRSVP is a key component of our enrolment process.”
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.